The government is pushing the pharmaceutical sector to move beyond generic manufacturing toward drug discovery and high-value innovation. Backed by the ₹10,000 crore Biopharma SHAKTI scheme, the initiative aims to bridge the research gap. Investors should track how domestic firms manage import dependence and increase R&D spending to improve long-term margins.
India’s pharmaceutical industry is at a strategic turning point as the government pushes for a transition from being a volume-based generic manufacturer to a global leader in drug discovery and innovation. At the inaugural Bharat Life Sciences Award (BLSA) held in New Delhi, officials and industry leaders underscored the need for the sector to evolve from the 'pharmacy of the world' into the 'laboratory of the world.' This shift is essential to move up the value chain, as current business models often rely heavily on high-volume production with thin margins.
To support this transition, the government has launched specific financial and infrastructure initiatives. The ₹10,000 crore Biopharma SHAKTI scheme, alongside the ₹5,000 crore PRIP (Promotion of Research and Innovation in Pharma) scheme, aims to strengthen domestic manufacturing of biologics and biosimilars. For investors, these schemes represent a significant government effort to lower capital costs and provide the necessary support for companies to invest in complex research platforms.
One of the most critical challenges facing the sector is the reliance on imported inputs. While India excels in formulations, it remains dependent on foreign suppliers for essential materials like resins, media, and cell lines required for advanced biologics manufacturing. This dependency creates a structural risk for companies, as it leaves profit margins vulnerable to supply chain disruptions and currency fluctuations. Investors may monitor whether companies successfully localise these inputs, which would improve both cost control and operational independence.
Another key metric to track is research and development (R&D) spending. Currently, there is a mismatch between India’s role as a major global player in healthcare and its research footprint. While India accounts for roughly 15% of the world's disease burden, it contributes to only 4% of global clinical trials. Industry experts have suggested that for Indian firms to compete globally in innovation, R&D budgets may need to rise from the current industry average of around 5% to 8-10% of total revenue.
Beyond financial allocation, regulatory efficiency remains a focus area. The government has stressed that companies must integrate regulatory strategy into the early stages of research, rather than treating it as a final hurdle. Future company updates regarding clinical trial approvals, the commissioning of new biopharma plants under government schemes, and improvements in proprietary drug pipelines will be important monitorables. These indicators will reveal which companies are successfully navigating the shift from simple manufacturing to high-value scientific advancement.